ISTO Technologies appoints chief commercial officer

ISTO Technologies Inc. announced the appointment of Phillip W. Kuhn as the company’s chief commercial officer.

According to a company press release, in this newly created position, Kuhn will oversee ISTO’s commercial strategy, including the execution of commercial activities relating to the sales, marketing and product development for InQu, the company’s bone graft extender and substitute used in spinal fusion and other orthopedic applications.

Prior to joining ISTO, Kuhn was vice president of marketing in Orthopedics U.S. at Orthofix International N.V. where he led all U.S. and Canadian upstream and downstream product management, medical education, sales training and marketing communications. He was also previously vice president in strategic marketing at Biologics and Spine, a Smith & Nephew company, where he led orthopedic biologic development in osteoarthritis and cartilage. Kuhn served in commercial leadership positions at medical products companies, including Abbott Laboratories, Baxter International, Cabot Medical, Ethicon Endo-Surgery and Indigo, both Johnson & Johnson companies, and Scimed, a Boston Scientific company.

“We are pleased to welcome Phil Kuhn, a strategic leader in the biologics space, to the ISTO team. Phil’s strong track record in developing new franchises and effective marketing programs while at Orthofix and Smith 7 nephew has direct relevance to ISTO’s plan to build sales of InQu while developing new biologics products for orthopedic and spinal applications,” George Dunbar, president and chief executive officer of ISTO, stated in the release. “His hire will help raise ISTO’s profile among potential industry partners and is consistent with our goal to add relevant domain expertise that strengthens our ability to successfully execute our global strategy.”